Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine mycobacterium ulcerans infection

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Martins, Teresa G ^a,b   Gama, José B ^a,b   Fraga, Alexandra G ^a,b   Saraiva, Margarida ^a,b   Silva, Manuel T ^c   Castro, António G ^a,b   Pedrosa, Jorge ^a,b  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; INDUCIBLE NITRIC OXIDE SYNTHASE; RIFAMPICIN; STREPTOMYCIN; ANTIINFECTIVE AGENT; IMMUNOSUPPRESSIVE AGENT;

ACID FAST BACTERIUM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL VIABILITY; BACTERIAL VIRULENCE; BURULI ULCER; CELLULAR IMMUNITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRAINING LYMPH NODE; EARLY INTERVENTION; FEMALE; FOOT PAD; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LEG SWELLING; LYMPH NODE; LYMPHOCYTE DEPLETION; LYMPHOCYTIC INFILTRATION; MACROPHAGE ACTIVATION; MOUSE; MYCOBACTERIUM ULCERANS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; SKIN DEFECT; STAINING; ANIMAL; BAGG ALBINO MOUSE; DISEASE COURSE; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; FLOW CYTOMETRY; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE; METABOLISM; METHODOLOGY;

BACILLI (CLASS); BACTERIA (MICROORGANISMS); MURINAE; MUS; MYCOBACTERIUM ULCERANS;

ANIMALS; ANTI-BACTERIAL AGENTS; BURULI ULCER; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; IMMUNITY, CELLULAR; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MYCOBACTERIUM ULCERANS; RIFAMPIN; STREPTOMYCIN;

EID: 84857676432     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032740     Document Type: Article

References (48)

1. Portaels F, Silva MT, Meyers WM, (2009) Buruli ulcer. Clin Dermatol 27: 291-305.
2. Asiedu K, Scherpbier R, Raviglione M, (2000) Buruli Ulcer, Mycobacterium ulcerans infection. World Health Organization WHO/CDS/CPE/GBUI/2000 1: 118.
3. George KM, Pascopella L, Welty DM, Small PL, (2000) A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun 68: 877-883.
4. Hong H, Demangel C, Pidot SJ, Leadlay PF, Stinear T, (2008) Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep 25: 447-454.
5. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999) Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283: 854-857.
6. Torrado E, Adusumilli S, Fraga AG, Small PL, Castro AG, et al. (2007) Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun 75: 3979-3988.
7. Torrado E, Fraga AG, Logarinho E, Martins TG, Carmona JA, et al. (2010) IFN-gamma-dependent activation of macrophages during experimental infections by Mycobacterium ulcerans is impaired by the toxin mycolactone. J Immunol 184: 947-955.
8. Amofah G, Asamoah S, Afram-Gyening C, (1998) Effectiveness of excision of pre-ulcerative Buruli lesions in field situations in a rural district in Ghana. Trop Doct 28: 81-83.
9. Teelken MA, Stienstra Y, Ellen DE, Quarshie E, Klutse E, et al. (2003) Buruli ulcer: differences in treatment outcome between two centres in Ghana. Acta Trop 88: 51-56.
10. Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, et al. (2005) Buruli ulcer recurrence, Benin. Emerg Infect Dis 11: 584-589.
11. World Health Organization (2004) Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). World Health Organization WHO/CDS/CPE/GBUI/2004 10: 33.
12. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, et al. (2005) Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 49: 3182-3186.
13. Bentoucha A, Robert J, Dega H, Lounis N, Jarlier V, et al. (2001) Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 45: 3109-3112.
14. Dega H, Bentoucha A, Robert J, Jarlier V, Grosset J, (2002) Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 46: 3193-3196.
15. Marsollier L, Prevot G, Honore N, Legras P, Manceau AL, et al. (2003) Susceptibility of Mycobacterium ulcerans to a combination of amikacin/rifampicin. Int J Antimicrob Agents 22: 562-566.
16. Chauty A, Ardant MF, Adeye A, Euverte H, Guedenon A, et al. (2007) Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 51: 4029-4035.
17. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, et al. (2010) Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375: 664-672.
18. Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, et al. (2010) Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 54: 3678-3685.
19. Torrado E, Fraga AG, Castro AG, Stragier P, Meyers WM, et al. (2007) Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun 75: 977-987.
20. Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, et al. (2005) Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun 73: 6299-6310.
21. Fraga AG, Cruz A, Martins TG, Torrado E, Saraiva M, et al. (2010) Mycobacterium ulcerans triggers T cell immunity followed by local and regional but not systemic immunosuppression. Infect Immun 79: 421-30.
22. Schutte D, Um-Boock A, Mensah-Quainoo E, Itin P, Schmid P, et al. (2007) Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis 1: e2.
23. Schutte D, Umboock A, Pluschke G, (2009) Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions. Br J Dermatol 160: 273-283.
24. Sarfo FS, Phillips RO, Ampadu E, Sarpong F, Adentwe E, et al. (2009) Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans. Clin Vaccine Immunol 16: 61-65.
25. Silva MT, Portaels F, Pedrosa J, (2009) Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect Dis 9: 699-710.
26. Dega H, Robert J, Bonnafous P, Jarlier V, Grosset J, (2000) Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 44: 2367-2372.
27. Gordon CL, Buntine JA, Hayman JA, Lavender CJ, Fyfe JA, et al. (2010) All-oral antibiotic treatment for Buruli ulcer: a report of four patients. PLoS Negl Trop Dis 4: e770.
28. McCune RM, Feldmann FM, Lambert HP, McDermott W, (1966) Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 123: 445-468.
29. Scanga CA, Mohan VP, Joseph H, Yu K, Chan J, et al. (1999) Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect Immun 67: 4531-4538.
30. O'Brien DP, Robson ME, Callan PP, McDonald AH, (2009) "Paradoxical" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust 191: 564-566.
31. Sopoh GE, Dossou AD, Brun LV, Barogui YT, Houezo JG, et al. (2010) Severe multifocal form of Buruli ulcer after streptomycin and rifampin treatment: comments on possible dissemination mechanisms. Am J Trop Med Hyg 83: 307-313.
32. Ruf MT, Chauty A, Adeye A, Ardant MF, Koussemou H, et al. (2011) Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? PLoS Negl Trop Dis 5: e1252.
33. Lefrancois S, Robert J, Chauffour A, Ji B, Jarlier V, (2007) Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin. Antimicrob Agents Chemother 51: 645-650.
34. Ji B, Chauffour A, Robert J, Lefrancois S, Jarlier V, (2007) Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 51: 3737-3739.
35. Shepard CC, McRae DH, (1968) A method for counting acid-fast bacteria. Int J Lepr Other Mycobact Dis 36: 78-82.
36. Denis M, (1991) Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. Cell Immunol 132: 150-157.
37. Chan J, Xing Y, Magliozzo RS, Bloom BR, (1992) Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 175: 1111-1122.
38. Chan J, Tanaka K, Carroll D, Flynn J, Bloom BR, (1995) Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis. Infect Immun 63: 736-740.
39. Lowenstein CJ, Alley EW, Raval P, Snowman AM, Snyder SH, et al. (1993) Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccharide. Proc Natl Acad Sci U S A 90: 9730-9734.
40. Kamijo R, Harada H, Matsuyama T, Bosland M, Gerecitano J, et al. (1994) Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 263: 1612-1615.
41. Rastogi N, Labrousse V, Goh KS, (1996) In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 33: 167-175.
42. Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, et al. (2011) Activities of rifampin, Rifapentine and clarithromycin alone and in combination against Mycobacterium ulcerans disease in mice. PLoS Negl Trop Dis 5: e933.
43. Zhang T, Li SY, Converse PJ, Almeida DV, Grosset JH, et al. (2011) Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection. Antimicrob Agents Chemother 55: 56-61.
44. Kibadi K, Boelaert M, Fraga AG, Kayinua M, Longatto-Filho A, et al. (2010) Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease). PLoS Negl Trop Dis 4: e736.
45. Silva MT, Macedo PM, Portaels F, Pattyn SR, (1984) Correlation viability/morphology in Mycobacterium leprae. Acta Leprol 2: 281-291.
46. Brooks JV, Furney SK, Orme IM, (1999) Metronidazole therapy in mice infected with tuberculosis. Antimicrob Agents Chemother 43: 1285-1288.
47. Repique CJ, Li A, Collins FM, Morris SL, (2002) DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge. Infect Immun 70: 3318-3323.
48. Sarfo FS, Le Chevalier F, Aka N, Phillips RO, Amoako Y, et al. (2011) Mycolactone diffuses into the peripheral blood of Buruli ulcer patients-implications for diagnosis and disease monitoring. PLoS Negl Trop Dis 5: e1237.